Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 9979
TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504408(US11040984, Compound 6)
Affinity DataIC50: 0.0150nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504412(US11040984, Compound 18)
Affinity DataIC50: 0.0150nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504411(US11040984, Compound 13)
Affinity DataIC50: 0.0160nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504410(US11040984, Compound 12)
Affinity DataIC50: 0.0170nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504403(US11040984, Compound 3)
Affinity DataIC50: 0.0200nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504415(US11040984, Compound 30)
Affinity DataIC50: 0.0210nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504414(US11040984, Compound 25)
Affinity DataIC50: 0.0220nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504413(US11040984, Compound 23)
Affinity DataIC50: 0.0380nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504412(US11040984, Compound 18)
Affinity DataIC50: 0.0500nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504415(US11040984, Compound 30)
Affinity DataIC50: 0.0520nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504411(US11040984, Compound 13)
Affinity DataIC50: 0.0520nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504414(US11040984, Compound 25)
Affinity DataIC50: 0.0690nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504408(US11040984, Compound 6)
Affinity DataIC50: 0.0700nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504410(US11040984, Compound 12)
Affinity DataIC50: 0.0850nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504403(US11040984, Compound 3)
Affinity DataIC50: 0.100nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Medshine Discovery

US Patent
LigandPNGBDBM504416(US11040984, Compound 33)
Affinity DataIC50: 0.114nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504413(US11040984, Compound 23)
Affinity DataIC50: 0.170nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504416(US11040984, Compound 33)
Affinity DataIC50: 0.290nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504402(US11040984, Compound 2)
Affinity DataIC50: 16.5nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504405(US11040984, Compound 4)
Affinity DataIC50: 30.1nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504402(US11040984, Compound 2)
Affinity DataIC50: 48.1nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Medshine Discovery

US Patent
LigandPNGBDBM504405(US11040984, Compound 4)
Affinity DataIC50: 55.4nMAssay Description:Buffer formulation: a buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BSA, 5 mM MgCl2, 0.1 mM Orthovanadate. After the buffer was formulated, an enzy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2021
Entry Details
Go to US Patent